Accurate measurements are the foundation of effective environmental management and decision-making. Through advanced ...

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

Knowledge is power, so here’s how to find power-gobbling data centers near you. Knowledge is power, so here’s how to find power-gobbling data centers near you. is a policy reporter at The Verge ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Public opposition to data centers is hardening as overwhelming majorities of Americans now oppose construction of the facilities in their communities, according to a newly released Gallup survey. The ...

Deal covers 352 MW IT capacity, potential value up to $25.1 bln Facility to support large-scale AI, designed around Nvidia’s latest architecture Development involves partners American Electric Power, ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

Developers of the proposed data center along W.Va. 62 north of Point Pleasant, West Virginia, have submitted their application for a construction permit to the West Virginia Department of ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...